Introduction {#Sec1}
============

Cholecystectomy has since long been the therapy of choice for elective treatment of patients with symptomatic gallstone disease. Acute cholecystitis (AC) is a well-known complication of gallbladder stone disease. Over the years, it has been claimed that AC can be primarily treated conservatively and then followed by delayed elective cholecystectomy. In recent decades, evidence has been gathered to show that early cholecystectomy for AC during the acute hospital stay is safe and cost-effective.[@CR1]--[@CR11] Lately, data have emerged from centers with great experience in laparoscopic surgery to show that early laparoscopic cholecystectomy is an attractive, feasible, and safe therapeutic strategy.[@CR12]--[@CR14] Recent meta-analyses concluded that early laparoscopic cholecystectomy appears to be safe and reduces total hospital stay.[@CR15]--[@CR17] Similar conclusions were also reached in a current Cochrane systemic review.[@CR18] A recent multicenter (*n* = 35 centers) randomized trial (*n* = 618 patients), studying early versus delayed cholecystectomy, finally settled the issue showing that laparoscopic cholecystectomy, when performed within 24 h of hospital admission, was significantly better as compared to conservative treatment regarding both morbidity and costs.[@CR13] Another controversial topic is the optimal timing of surgery in AC, where one of the issues is whether it should be operated early (i.e., within the first 48 to 96 h) or delayed (within the same hospital stay), depending on the actual practical and logistic circumstances. Studies, incorporating a limited number of patients, have indicated that the best time window to operate AC might be within the first 48 to 96 h.[@CR5],[@CR8] A French nationwide registry study has recently shown that operation within 3 days after admission is recommended in patients with acute cholecystitis.[@CR19] To address a similar question within an RCT, it would require a large number of patients to create sufficient power for testing the hypotheses, which basically preclude the completion of trials within reasonable time limits. National quality registry studies can act as a complement to RCTs. Registries enable data collection on large-scale patient cohorts, permitting analyses with good statistical power. Corresponding registry studies have been able to address clinical questions that, due to statistical, time, and financial constraints, would never have been studied in RCTs, for example the value of intraoperative cholangiography in preventing bile duct injury in gallstone surgery.[@CR20]--[@CR21] The aim of this study was therefore to compare the outcomes for patients operated on for AC in the entire country, during a 9-year period, with particular focus on the time elapsed from admission to hospital until the cholecystectomy was carried out, and the impact of these time periods on the intra- and postoperative adverse events.

Methods {#Sec2}
=======

Swedish Registry of Gallstone Surgery and Endoscopic Retrograde Cholangiopancreatography (GallRiks) {#Sec3}
---------------------------------------------------------------------------------------------------

The Swedish Registry of Gallstone Surgery and Endoscopic Retrograde Cholangiopancreatography (ERCP) was founded on May 2005 by the Swedish National Board of Health and Welfare, the Swedish Surgical Association, and the Swedish Society of Laparoscopic Surgery. It is financially supported by the Swedish national health authorities. On an annual basis, approximately 20,000 procedures (12,000 cholecystectomies and 8000 ERCPs) are registered. The aim of the registry is to obtain continuously updated information regarding indications, outcomes, and patient satisfaction in order to ensure high-quality care of patients needing cholecystectomy, regardless of where in Sweden they are managed.[@CR22] The operating surgeon registers the procedure online, preferably during the operation or immediately after. A 30-day follow-up is administered by the local coordinator at each participating hospital. The follow-up is also registered online. The validity of data is monitored by independent reviewers, who visit the participating hospitals at least once every third year and compare the online registrations with the corresponding patient records. The validation of GallRiks has demonstrated high correctness and completeness of data and no failure to report serious adverse events.[@CR23] The registry attained an overall national coverage of approximately 90 % during the actual enrolment period.

Study Design {#Sec4}
------------

We conducted a nationwide, population-based, nested case-control study within the cohort of cholecystectomies entered into GallRiks between 1 January 2006 and 31 December 2014. Index cholecystectomies with a complete 30-day follow-up were identified. From this cohort, procedures performed with the indications of malignancy, concomitant major surgery in conjunction with cholecystectomy, as well as acute pancreatitis were excluded, leaving 87,108 cholecystectomies for analysis (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1The procedures included in the analysis

Definitions {#Sec5}
-----------

For the purpose of this paper and in accordance with the descriptions in the GallRiks database, the following definitions were applied.*Intraoperative adverse events* are defined as bleeding, bile duct injury, gut perforation, or any other reason for the cholecystectomy to be terminated prematurely.*Intraoperative bleeding demanding intervention* is defined as any bleeding requiring blood transfusion or conversion to open surgery. Bleeding that is controlled completely with diathermy, clips, or sutures is not considered to be intraoperative bleeding demanding an intervention. Data are not filed on the volume of blood loss and number of transfused blood units.*Bile duct injury* (*BDI*) is defined as intraoperatively registered (a) BDI ≤1/3 of the diameter, (b) BDI \>1/3 of the diameter, (c) resection of a substantial part of the bile duct wall, or (d) complete transection of the bile duct.*Postoperative adverse events* are defined as any complication during the 30-day follow-up period that required some form of medical or surgical intervention.

Statistics {#Sec6}
----------

Statistical analysis was performed using JMP 12.1.0 (64-bit) (SAS Institute, Inc., Cary, NC, USA). Comparisons of patient- and procedure-related characteristics were presented in contingency tables, with pairwise differences analyzed with Pearson's chi-square test and presented as *P* values. The association between acute cholecystitis and the time of operation after admission as well as the risk of adverse events and mortality were analyzed using multivariable logistic regression modeling. Variables that were statistically significant in univariate analysis were included in the multivariate model as described by Hosmer et al.[@CR24]

In the multivariate analysis, the outcome was adjusted for age (dichotomized into more or less than 50 years), gender, comorbidity (dichotomized into ASA 1--2 and ASA ≥3), acute or scheduled surgery, indication for and type of surgery, as well as if the patients had a history of previous acute cholecystitis.

The models were tested for multicollinearity and effect modification and finally assessed for goodness of fit. The effects of analyzed variables were presented as odds ratios (ORs) for adverse events with 95 % confidence intervals.

Ethical considerations {#Sec7}
----------------------

The regional research ethics committee at Karolinska Institutet, Stockholm, Sweden, approved the study.

Results {#Sec8}
=======

Between 1 January 2006 and 31 December 2014, 100,258 cholecystectomies were registered in GallRiks of which 87,108 met the inclusion criteria (Fig. [1](#Fig1){ref-type="fig"}). The demographics of the study population, the surgical technique for the cholecystectomy, antibiotic use, and length of hospital stay for patients with or without AC are given in Table [1](#Tab1){ref-type="table"}. For all outcome measures given, except for the length of postoperative hospital stay after open cholecystectomy, the two groups (AC versus no AC) differed significantly. In the AC group, there was a significantly increased risk of intra- and postoperative adverse events (Table [2](#Tab2){ref-type="table"}). Neither the 30- nor the 90-day mortality risk, however, differed significantly in the multivariate analysis (Table [2](#Tab2){ref-type="table"}). In the subgroup of patients operated on with cholecystectomy (laparoscopic or open) for AC, the majority had an operation during the first day after admission (39.2 %) followed by those who had an operation on the second day (27.3 %). Cholecystectomy on the admission day was performed in 11.9 % of the AC patients (Fig. [2](#Fig2){ref-type="fig"}). The conversion rate in the latter group increased in a stepwise manner from 16.6 % on admission day to 27.8 % on \>4 days after admission (Fig. [2](#Fig2){ref-type="fig"}). The multivariate analysis of the AC patients, with regard to the risk of intraoperative adverse events, revealed a significantly lower risk for adverse event (AE) when the operation was done on the first or second day after admission (Table [3](#Tab3){ref-type="table"}). The risk of intraoperatively detected bile duct injuries was, however, lowest when the cholecystectomy was done on the day of admission with a thereafter day-by-day stepwise increased risk (Table [3](#Tab3){ref-type="table"}). The risk of postoperative AE was significantly lower in patients operated within the first 4 days after admission as compared to those operated 5 days or more after admission (Table [3](#Tab3){ref-type="table"}). The 30-day mortality risk was significantly lower when operated during the first day after admission, and even the 90-day mortality risk was significantly reduced if the operation was completed within 3 days of admission as compared to those operated 5 days or more thereafter (Table [3](#Tab3){ref-type="table"}). Intraoperative blood loss was not affected by the time elapsed from admission.Table 1Demographics of acute cholecystitis (AC) and no ACAC (*n* = 15,760)No AC (*n* = 71,348)*Pn*%*n*%Gender Females837653.1550,52670.82*\<0.0001* Males738446.8520,82229.18Age (years)^a^ \>50973161.9733,07346.42*\<0.0001* ≤50597138.0338,16953.58ASA 1--213,79287.5166,96593.86*\<0.0001* ≥3196812.4943836.14Op technique LC (Op started with laparoscopic technique)12,52279.4568,80396.43*\<0.0001* Converted^b^252020.1236225.26*\<0.0001*Antibiotics Prophylactic453128.7511,85916.62*\<0.0001* Treatment796350.5330024.21 No antibiotics326620.7256,48779.17Hospital stay (days)^c^MeanSEMMeanSEM Length of postop stay3.520.041.590.01*\<0.0001* LC postop stay2.980.041.430.01*\<0.0001* OC postop stay5.600.115.690.150.5988^a^Missing 164^b^Excluded 5783 OCs^c^Missing 85 Table 2Risk of intra- and postoperative adverse events (AEs) in acute cholecystitis (AC) and no AC, respectivelyNumberPercentUnivariateMultivariate^a^AENo AEOR (95 % CI)*P*OR (95 % CI)*P*Intraop AE No AC202869,3202.841.0 (reference)1.0 (reference) AC61815,1423.921.40 (1.27--1.53)*\<0.0001*1.23 (1.12--1.35)*\<0.0001*Intraop bleeding No AC49670,8520.701.0 (reference)1.0 (reference) AC23415,5261.482.15 (1.84--2.51)*\<0.0001*1.54 (1.30--1.82)*\<0.0001*Intraop bile duct injury No AC20171,1470.281.0 (reference)1.0 (reference) AC6715,6930.431.51 (1.14--1.98)*0.0048*1.44 (1.08--1.90)*0.0137*Postop AE No AC525066,0987.361.0 (reference)1.0 (reference) AC189613,86412.031.72 (1.63--1.82)*\<0.0001*1.38 (1.26--1.51)*\<0.0001*Mortality (≤30 days) No AC4771,3010.071.0 (reference)1.0 (reference) AC7315,6870.467.06 (4.91--10.25)*\<0.0001*1.25 (0.67--2.22)0.4720Mortality (≤90 days) No AC10071,2480.141.0 (reference)1.0 (reference) AC12915,6310.825.88 (4.53--7.65)*\<0.0001*1.04 (0.72--1.49)0.8137^a^Adjusted for sex, age, ASA, acute/scheduled surgery, indication, type of surgery, and previous acute cholecystitis Fig. 2Acute cholecystitis (AC). Adverse events in relation to the time of surgery after admission Table 3Risk of adverse events (AEs) in acute cholecystitis in relation to the timing of surgery after admission to hospitalTime between admission and treatment (days)Number (*n* = 15,189^a^)UnivariateMultivariate^a^YesNo%OR (95 % CI)*P*OR (95 % CI)*P*Intraoperative AE ≥5447095.841.0 (reference)1.0 (reference) 4377184.900.83 (0.53--1.30)0.41660.88 (0.56--1.38)0.5819 37817034.380.74 (0.51--1.09)0.12210.81 (0.55--1.19)0.2811 214639973.520.59 (0.42--0.84)***0.0041***0.66 (0.47--0.95)*0.0261* 121257453.560.59 (0.43--0.84)***0.0038***0.67 (0.49--0.96)***0.0285*** Admission day7117293.940.66 (0.45--0.98)***0.0393***0.74 (0.50--1.10)0.1377Intraoperative bleeding ≥5157381.991.0 (reference)1.0 (reference) 4157401.991.00 (0.48--2.07)0.99411.14 (0.55--2.38)0.7254 32917521.630.81 (0.44--1.57)0.52710.97 (0.52--1.88)0.9187 26140821.470.74 (0.43--1.35)0.30520.94 (0.54--1.73)0.8347 18058771.340.67 (0.40--1.21)0.17710.86 (0.50--1.57)0.6054 Admission day2817721.560.78 (0.42--1.50)0.44170.97 (0.52--1.88)0.9255Bile duct injury intraoperatively ≥577460.931.0 (reference)1.0 (reference) 447510.530.57 (0.15--1.89)0.35860.59 (0.15--1.97)0.3950 31217690.670.72 (0.29--1.95)0.50370.78 (0.31--2.11)0.6106 21641270.390.41 (0.18--1.08)*0.0691*0.45 (0.19--1.18)0.1007 12259350.370.40 (0.18--1.00)*0.0505*0.43 (0.19--1.11)*0.0780* Admission day317970.170.18 (0.04--0.64)***0.0081***0.19 (0.04--0.68)***0.0107***Postoperative AE ≥513062317.261.0 (reference)1.0 (reference) 48067510.600.57 (0.42--0.76)***0.0002***0.61 (0.45--0.82)***0.0012*** 3209157211.730.64 (0.50--0.81)***0.0002***0.71 (0.56--0.90)***0.0055*** 2480366311.590.63 (0.51--0.78)***\<0.0001***0.72 (0.58--0.90)***0.0041*** 1700525711.750.64 (0.52--0.79)***\<0.0001***0.73 (0.60--0.91)***0.0044*** Admission day227157312.610.69 (0.55--0.88)***0.0024***0.78 (0.62--1.00)***0.0468***Mortality (≤30 days) ≥5107431.331.0 (reference)1.0 (reference) 4107451.321.00 (0.41--2.44)0.99521.36 (0.54--3.43)0.5030 3817730.450.34 (0.13--0.85)***0.0223***0.49 (0.18--1.28)0.1465 21641270.390.29 (0.13--0.66)***0.0042***0.52 (0.23--1.21)0.1245 11859390.300.23 (0.11--0.51)***0.0007***0.40 (0.18--0.93)***0.0344*** Admission day1017900.560.42 (0.17--1.02)***0.0539***0.62 (0.25--1.56)0.3096Mortality (≤90 days) ≥5227312.921.0 (reference)1.0 (reference) 4137421.720.58 (0.28--1.15)0.11980.77 (0.37--1.57)0.4794 31517660.840.28 (0.14--0.54)***0.0002***0.40 (0.20--0.79)***0.0085*** 23041130.720.24 (0.14--0.43)***\<0.0001***0.42 (0.24--0.76)***0.0048*** 12959280.490.16 (0.09--0.29)***\<0.0001***0.28 (0.16--0.51)***\<0.0001*** Admission day1717830.940.32 (0.16--0.60)***0.0004***0.47 (0.24--0.91)***0.0253***In 571 of the 15,760, LOS was not correctly stated. Values in bold-italic are statistically significant (*P*\<0.05). Values in italic are not statistically significant but indicate a trend^a^Adjusted for sex, age, ASA, type of surgery, and previous acute cholecystitis

Discussion {#Sec9}
==========

This study represents one of the largest patient cohorts addressing the correlation between the time elapsed from hospital admission for AC and definitive surgery and the risk for intra- and postoperative AE. We found that the optimal time slot for surgery was within the first 2 days after hospital admission. Cholecystectomy on admission day was performed in close to 12 % of the AC patients, and the risk of intraoperatively detected bile duct injuries was lowest when the cholecystectomy was done on the day of admission with a thereafter day-by-day stepwise increase. These findings support the findings in the literature of the beneficial effect of early surgery on AC.[@CR5],[@CR8],[@CR19] This information is clinically relevant since the majority of minor bile duct lesions are detected intraoperatively and repair is usually attempted at the index procedure with satisfactory results,[@CR25] an observation which is not entirely consistent with the international experiences.[@CR20],[@CR21] However, in the multivariate analysis, we observed a significantly lower risk for AE when the operation was done on the first or second day after admission. These differences in morbidity were also translated into 30-day mortality risk, which were significantly lower when the cholecystectomy was completed during the first day after admission. Even the 90-day mortality risk was significantly reduced for those operated within 3 days of admission. Although operation on admission day in most of our assessments has a significantly better outcome than in those being operated 5 days or more after admission, the frequency of adverse events was somewhat higher compared to an operation performed 1 or 2 days thereafter. The reason for these findings may be found in the fact that some patients arrive at the emergency unit in a bad general condition where time is required for resuscitation and stabilization of the patient, before embarking on definitive surgery. Furthermore, if the patient with acute cholecystitis arrives at the hospital during non-office hours and is immediately scheduled for cholecystectomy, the issue of not being able to offer the highest level of laparoscopic surgical expertise may have a bearing on the outcome. Nevertheless, these issues did not translate into an enhanced risk for BDI.

In a similar analysis of 4113 prospective cholecystectomies performed on patients with acute cholecystitis as reported from the Swiss Association of Laparoscopic and Thoracoscopic Surgery (SALTS) database, the authors concluded that immediate surgery (surgery on the day of admission or at the latest within 24 h of admission) significantly reduced the risk of conversion from laparoscopic to open surgery, which can be used as a proxy variable for the safety and accuracy of the respective operations.[@CR12] This is to some extent in line with our study, where the conversion rate, when operation occurred on admission day, was 16.6 % and then increased in a linear fashion to 27.8 % in patients operated on 4 days later. However, whereas the technical conditions for surgery may be optimal on admission day, due to less extent of the inflammation, the findings in our study of a better outcome when patients are operated on the first or second day after admission may indicate that other factors, like the general condition of the patient, mandate attention in order to optimize the outcome.

Studies on the management of patients with AC in routine surgical practice have revealed that basically, no major changes have occurred over recent years.[@CR14],[@CR26],[@CR27] This illustrates the problems and challenges in the implementation of evidence-based guidelines for the treatment of AC. To some extent, this may be explained by a larger proportion of elderly patients with high comorbidity; however, one cannot rule out a widespread conservative attitude with resistance to new evidence-based approaches.[@CR26] The slow adaptation to new guidelines could have several other explanations such as local logistic problems and lack of resources for acute surgery. There may also be a proportion of patients with a long duration of symptoms before seeking medical attention, resulting in reluctance to an emergency operation.

The strengths of the current analyses are represented by the magnitude of the database, extracted from the national Swedish Registry of Gallstone Surgery and ERCP (GallRiks), which describes the outcome of cholecystectomies performed at nearly all hospitals in Sweden in routine clinical practice. Thus, regional differences, as well as differences in catchment areas and profiles of the hospitals, can be compensated for. An additional strength of the study is that the data are registered prospectively by the respective surgeons, online, at the time of completion of the operation.

We also recognize that there are some obvious limitations of the study. GallRiks is a national quality register for gallstone surgery and ERCP, and accordingly, the quality and relevance of some clinical data can rightfully be questioned since these are not entered into the registry as a part of a randomized controlled trial protocol with the specific, dedicated aim of addressing specific questions. A further limitation of the register relates to the definition of the variable postoperative adverse event. Although AEs are defined in the Web protocol, these can be interpreted differently by the local coordinators at the participating hospitals. In order to minimize this risk, a list of the most common postoperative adverse events like pancreatitis, cholangitis, bile leakage, and deep venous thrombosis, just to mention a few, will from August 2016 and onwards be visible as predefined options to the local coordinator as an aid to minimize the interobserver variability. However, for the data presented in this study, the coordinator had to decide first whether a postoperative adverse event prevailed before the respective alternatives were chosen. Another possible limitation of these data is a possible risk of selection bias where the reporting surgeon may avoid reporting on negative adverse events related to the surgical intervention. To avoid this, special attention has been directed towards corresponding issues, in order to minimize loss of data quality. An independent coordinator at each participating hospital reviews each individual intervention and reports on imbalances at a compulsory 30-day follow-up. The GallRiks board also undertakes regular validation visits to all the participating hospitals, in order to ensure the accuracy and validity of the registered data. In order to adjust for the possible skewness of data and other confounding factors such as gender, age, comorbidity (American Society of Anesthesiologists classification scale), emergent or scheduled surgery, indication for and type of surgery, as well as a history of previous acute cholecystitis, these were managed through the multivariate analysis. It needs to be pointed out that the time elapsed from admission to the operation was only possible to calculate according to the final date of surgery by the date of admission. Accordingly, the exact time in hours between operation and surgery could not be captured. Likewise, the exact time from onset of symptoms of acute cholecystitis to admission is not registered in GallRiks. Finally, it must be emphasized that GallRiks is designed with the Swedish Health Care System in mind and that the findings in this study must be interpreted cautiously from an international perspective. Accordingly some aspects on the current problem related to the management of AC can, due to methodological limitations, only be addressed by indirect measures.

Conclusion {#Sec10}
==========

The optimal timing of cholecystectomy for patients with acute cholecystitis appears to be within the first 2 days of hospital admission. However, the somewhat higher frequency of adverse events after operations performed on the admission day emphasizes the importance of optimizing the patient before surgery as well as ensuring that the highest surgical resources are available at the time of operation.
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